The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Mesenchymal Stem Cell‐Derived Extracellular Vesicles with High PD‐L1 Expression for Autoimmune Diseases Treatment
Abstract
Autoimmune diseases are the third most common disease influencing the quality of life of many patients. Here, a programmed cell death‐ligand 1 + (PD‐L1) mesenchymal stem cell (MSC) derived extracellular vesicles (MSC‐sEVs‐PD‐L1) using lentivirus‐mediated gene transfection technology is developed for reconfiguration of the local immune microenvironment of affected tissue in autoimmune diseases. MSC‐sEVs‐PD‐L1 exhibits an impressive ability to regulate various activated immune cells to an immunosuppressed state in vitro. More importantly, in dextran sulfate sodium‐induced ulcerative colitis (UC) and imiquimod‐induced psoriasis mouse models, a significantly high accumulation of MSC‐sEVs‐PD‐L1 is observed in the inflamed tissues compared to the PD‐L1+ MSCs. Therapeutic efficiency in both UC and psoriasis mouse disease models is demonstrated using MSC‐sEVs‐PD‐L1 to reshape the inflammatory ecosystem in the local immune context. A technology is developed using MSC‐sEVs‐PD‐L1 as a natural delivery platform for autoimmune diseases treatment with high clinical potential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Martins, F., Sofiya, L., Sykiotis, G. P., Lamine, F., Maillard, M., Fraga, M., Shabafrouz, K., Ribi, C., Cairoli, A., Guex-Crosier, Y., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0218-0 · Cited by 2,314
Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities
Galipeau, J., & Sensébé, L. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.05.004 · Cited by 1,819
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Doroshow, D. B., Bhalla, S., Beasley, M. B., Sholl, L. M., Kerr, K. M., Gnjatic, S., Wistuba, I. I., Rimm, D. L., Tsao, M. S., & Hirsch, F. R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00473-5 · Cited by 1,575
Targeting Interleukin-6 Signaling in Clinic
Kang, S., Tanaka, T., Narazaki, M., & Kishimoto, T. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.026 · Cited by 904
Kinase inhibition in autoimmunity and inflammation
Zarrin, A. A., Bao, K., Lupardus, P., & Vucic, D. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0082-8 · Cited by 431
Sugiura, D., Maruhashi, T., Okazaki, I.-M., Shimizu, K., Maeda, T. K., Takemoto, T., & Okazaki, T. (2019) · Science · doi:10.1126/science.aav7062 · Cited by 386
Cited by
Signaling pathways and targeted therapies for psoriasis
Guo, J., Zhang, H., Lin, W., Lu, L., Su, J., & Chen, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01655-6 · Cited by 427
Recent applications of immunomodulatory biomaterials for disease immunotherapy
Dai, H., Fan, Q., & Wang, C. (2022) · Exploration · doi:10.1002/exp.20210157 · Cited by 268
Self-citationImmunogenicity of Extracellular Vesicles
Xia, Y., Zhang, J., Liu, G., & Wolfram, J. (2024) · Advanced Materials · doi:10.1002/adma.202403199 · Cited by 256
Strategies for Small Extracellular Vesicle-Based Cancer Immunotherapy
Chen, Y., Tang, S., Cai, F., & Wan, Y. (2024) · Research · doi:10.34133/research.0421 · Cited by 26
Lin, X., Cai, L., Nie, M., Wu, X., Liang, G., Shang, L., & Zhao, Y. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.144118 · Cited by 15
Metadata
- Authors
- Xu, F., Fei, Z., Dai, H., Xu, J., Fan, Q., Shen, S., Zhang, Y., Ma, Q., Chu, J., Peng, F., Zhou, F., Liu, Z., & Wang, C.
- Venue
- Advanced Materials
- Publisher
- Wiley
- Published
- 2021-10-23
- Volume
- 34
- Issue
- 1
- Pages
- e2106265-e2106265
- ISSN
- 0935-9648 (ISSN-L)
- 1521-4095
- OpenAlex
- W3203559595
- Cited by
- 176
- References
- 7
- FWCI
- 7.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.